# CapsoVision

its CapsoCam Plus capsule endoscopy device has cleared approval for pediatric use, with the company reporting its first-quarter 2026 financial results as a public company.

Source: https://en.bioecon.ru/companies/capsovision/
Updated: 2026-07-20

- Country: United States

## Verifiable facts

| Fact | Value | Source |
| --- | --- | --- |
| Funding | $14 million private placement closed on March 16, 2026 | https://www.globenewswire.com/news-release/2026/03/20/3259701/0/en/CapsoVision-Announces-14-Million-Private-Placement-Financing.html, https://www.sec.gov/Archives/edgar/data/1378325/000137832526000019/cv-20260514xex991q12026ear.htm |
| Revenue | $3.6 million for second quarter 2026; $2.8 million for first quarter 2026 | https://investors.capsovision.com/node/7531/pdf, https://www.biospace.com/press-releases/capsovision-reports-first-quarter-2026-financial-results, https://www.globenewswire.com/news-release/2026/05/14/3295350/0/en/CapsoVision-Reports-First-Quarter-2026-Financial-Results.html, https://www.sec.gov/Archives/edgar/data/1378325/000137832526000019/cv-20260514xex991q12026ear.htm |
| Regulatory approval | FDA clearance for pediatric use (age two and above) announced January 9, 2025 | https://capsovision.com/capsocam-plus/, https://capsovision.com/news/, https://investors.capsovision.com/news-releases/news-release-details/capsovisions-capsocam-plusr-capsule-endoscopy-system-receives |
| Certification | ISO 27001 certification achieved December 4, 2020 | https://capsovision.com/news/ |
| Production site | Components sourced primarily from Asia, particularly Taiwan and Japan [medium confidence] | https://www.sec.gov/Archives/edgar/data/1378325/000119312525116894/0001193125-25-116894.txt, https://www.sec.gov/Archives/edgar/data/1378325/000119312525149285/d916440ds1a.htm |

Independent sources: biospace.com, globenewswire.com, sec.gov

## Technologies

- [Ingestible biosensors / smart pills](https://en.bioecon.ru/technology/ingestible-biosensors-smart-pills/)